Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib + Pembrolizumab in HRRm/HRD-Positive Advanced Solid Tumors
NCT04123366Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2019
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 23
01
Overview
A Phase 2 trial of olaparib, pembrolizumab in solid tumor, sponsored by Merck & Co.. Started Nov 2019; status: completed.
02
Drugs
olaparibpembrolizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04123366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123366.